Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 17%
Hold 58%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is expected to have a positive outlook as it continues to generate strong results from its upcoming catalysts, including initiation of various trials and topline results in 2H26. These upcoming catalysts, along with Exelixis' current partnerships and expected FDA approval for zanzalintinib, make it a potential "pipeline-in-a-product" play with room for growth in the medullary thyroid, kidney, liver, and other cancer markets. Additionally, Exelixis' strong financial performance and increasing sales trajectory make it likely to outperform the market, as seen with its expected increase in price target to $55 (DCF-derived) from $50. Therefore, Exelixis presents a strong opportunity for investors seeking potential growth in the biopharmaceutical industry.

Bears say

Exelixis is facing several challenges that could negatively impact its financials and stock performance. These include a crowded market for its cancer treatments, with competition from established players and new entrants, and a low success rate for its early-stage pipeline programs. Despite strong cash generation and share repurchase programs, there is currently a lack of momentum drivers for the stock. Additionally, the company's recent data updates for its lead product, cabozantinib, have shown only modest improvements, raising doubts about its potential for sustained success.

Exelixis (EXEL) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 17% recommend Buy, 58% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 12 analysts, Exelixis (EXEL) has a Buy consensus rating as of Aug 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.